Corcept Therapeutics Updates Cushing’s Syndrome Development and Recent Financing
MENLO PARK, CA–(Marketwire – 05/03/10) – Corcept Therapeutics Incorporated (NASDAQ: CORT – News ), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today updated the status of enrollment in its Phase 3 trial in Cushing’s Syndrome and discussed its recent financing. “Forty-five of fifty patients have been …

Read more on Marketwire via Yahoo! Finance

iCo Therapeutics Announces Year-End 2009 Financial Results
VANCOUVER, BRITISH COLUMBIA– – iCo Therapeutics Inc. today reported financial results for the year ended December 31, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles .

Read more on CCNMatthews via Yahoo! Finance